singlecell rna sequence scrnaseq technology provide opportunity profile cell component within tme investigate role play tumor occurrence development.15 contrast standard bulk population sequence provide average value scrnaseq allow molecular distinction cell type within complex population include malignant cell immune cell stromal cell tme.16 addition ith cell type well interaction multicellular component could also investigate scrnaseq.17 however scdnaseq scatacseq approach apply archival specimen scrnaseq method require viable cell suspension fresh tissues,15 hinder lack surgical specimen sclc singlecell transcriptomic profile analysis perform cancer type still scrnaseq study match primary tumor pt normal lung tissue adjacent tumor nats relapse tumor rts human sclc.18,19,20 perform modify singlecell tag reverse transcription sequence strtseq fresh sample primary match adjacent normal lung tissue 11 patient limitedstage sclc reveal heterogeneous cellular architecture malignant cancer singlecell resolution describe gene expression atlas sclc tumor singlecell level perform modify strtseq match pt nats rts 11 sclc patient undergo surgical resection fig 1a supplementary table s1 patient include male 911 heavy smoke history consistent typical sclc characteristic singlecell transcriptomes total 4911 cell pt n 3365 nats n 1274 relapse tumor rts n 272 obtain initial quality control fig 1bd supplementary fig s1b pt rts distinguish 1954 malignant 1683 nonmalignant cell epithelial origin cluster pattern infer largescale chromosomal copy number variation cnvs epithelial biomarkers epcam krt818 uniformly express high level across sclc malignant cell krt719 cdh1 sfn partially express individual malignant cell fig 1e krt family gene include krt 56a6b42p1314151617 widely express solid tumor nonsmall cell lung cancer nsclc head neck squamous cell carcinoma hnscc rarely express sclc represent cancer typespecific expression profile fig 1e notably malignant cluster contain cell patientspecific subpopulation represent significant intertumor heterogeneity fig 1b c. contrast nonmalignant cell tme cell nat identify expression know marker tend cluster together cell type cluster contain cell different patient indicate cell type expression state largely consistent across patient although vary proportion fig 1c supplementary fig s1b c. infer cnvs confirm separation malignant cell nonmalignant cell normal karyotype also reveal widespread heterogeneity sclc genome level fig 1f supplementary fig s1df specifically cnvs show intertumor heterogeneity 5q loss exhibit intertumor heterogeneity ith p3 normal p2 p4 p5 p12 p13 5q loss p7 p10 p11 partial 5q loss next perform bulk dna sequence multiregion tissue match use scrnaseq cnvs call lowpass wholegenome sequence wgs data include uniform chromosome 10 11p 15 16q 17p loss 8 9 18 gain p7 15 17p loss p10 1 14 17q 18 gain p11 supplementary fig s1df firmly validate infer cnvs scrnaseq data result also reveal 5q loss associate increase risk recurrence cohort spatial ith sclc supplementary fig s1g singlecell profile nonmalignant cell highlight composition sclc fig 2a b. compare nats pt exhibit increase fraction lymphocyte le myeloid cell infiltration fig 2c indicate significant role play adaptive immunity within tme significant role play innate immune response normal lung tissue reclustered cell myeloid cell power relatively large number dataset cell nats tme mainly compose cd8positive cell express high level cytotoxic marker gzmabhk prf1 nkg7 ifng gnly cxcl13 imply significant immune surveillance sclc supplementary fig s2a compare cytotoxic cell nats observe increase diversity cell tme include four heterogeneous activation state base na07veness cytotoxicity exhaustion proliferation property fig 2d e. calculate score cell state base average expression level marker gene well define either dataset previously publish study exhaustion score exhibit positive correlation cytotoxicity score consistent observation metastatic melanoma negative correlation na07veness score fig 2f proliferate cell characterize high expression cell cyclerelated gene mki67 top2a imply cell status undergo extensive clonal expansion cell population also express high level cytotoxic gene median level coinhibitory receptor fig 2e next examine expression preference individual patient show supplementary fig s2b proliferate cell cluster compose cell almost patient include imply uniform existence cell status sclc patient supplementary fig s2b contrast cell cluster mainly compose cell one two patient example cluster 5 mainly p2 cluster 1 p1 p14 cluster 3 mainly p7 p12 supplementary fig s2b detail classification cell sclc also reveal expression pattern marker dysfunction exhaustion e.g. pdcd1 ctla4 havcr2 lag3 tigit layn might serve immunotherapy target supplementary fig s2c havcr2 exhibit highest expression level exhaust cell subcluster mainly p2 ctla4 preferentially express cell subclusters sclc tme layn associate suppressive function exhaust cd8 cell nsclc liver cancer however exhibit sporadic expression sclc heterogeneous state coinhibitory receptor expression preference sclc cell provide potential immunotherapy target sclc also suggest might increase benefit select patient respond immunotherapy next perform unsupervised cluster analysis myeloid cell nats tme identify heterogeneous cell type base wellannotated marker gene reclustering reveal essentially major know myeloid cell lineage include mast cell neutrophil monocyte dendritic cell dc macrophage cluster reveal four distinct macrophage cluster three lungresident alveolar macrophage am1 am2 am3 one tumorassociated macrophage tam fig 2g supplementary fig s2d e. use singlecell data publish study also validate existence three four monomacro subpopulation identify study include tam am2 am3 supplementary fig s2gj macrophage lineage seem exhibit distinct tissue distribution am1 compose exclusively cell nats tam tme am2 am3 compose cell nats tme imply could derive precursor localize lung tissue potential migratory feature two subtypes tumor tissue adjacent normal lung tissue am2 exhibit higher expression level major histocompatibility complex mhc cluster ii molecule include hladqa2 hladrb6 hladrb5 am1 imply enhance antigenpresenting ability cluster fig 2h am3 feature cell cycleassociated gene mki67 aurkb cdk1 aspm similar gene expression pattern am2 tam suggest strong proliferative property potential state transition ability cluster fig 2h contrast tam tme sclc express high level tcf4 il2ra pla2g7 gal3st4 pltp cmklr1 adamdec1 mmp12 fig 2h suggest immunosuppressive feature thus provide potential target sclc immunotherapy ido1 induce inflammation within tme promote tolerogenic environment immunosuppressive myeloid cell population highly express dc sclc tme supplementary fig s2f singlecell data reveal diverse immune cell state sclc microenvironment may help better understand develop novel treatment strategy sclc analyze expression heterogeneity malignant compartment separate malignant cell run umap although cell group tumor origin represent extensive intertumor heterogeneity many tumor contain separate subclusters indicate significant ith transcriptome level fig 3a supplementary fig s3a degs mainly include respond immune stimulate mhc class molecule cd74 ido1 isg15 suggest close interaction malignant immune cell tme patient sclcp2 fig 3b supplementary fig s3b supplementary table s3 addition key tfs relate sclc tumor subtypes ascl1 neurod1 pou2f3 find differentially express cohort describe follow section addition potential treatment target biomarkers sclc myc parp1 slfn11 cdk7 bcl2 cd274 find differentially express individual cell highlight need patient selection improve target therapeutic strategy thus intertumor heterogeneity malignant cell reflect difference interaction tme component sclc subtypes different drug sensitivity explore biological state process involve among individual malignant cell perform gsea use 'hallmark gene set collection gene high variability degs mainly involve hallmark g2m checkpoint inflammatory response interferon α response interferon γ response tnfα signal via nfκb emt kras signal hypoxia fig 3c supplementary table s4 pearson correlation analysis reveal hallmark could categorize program associate proliferation immune response hypoxiarelated hallmark fig 3c notable feature module analysis activity proliferation program large proportion cell tumor range 19.8 sclcp12 75.4 sclcp3 fig 3d proliferation program include mki67 typical biomarker use clinic indicate proliferate property sclc top2a topoisomerase ii target etoposide frequently use sclc treatment combination platinum supplementary fig s3c thus proliferation program closely associate clinically report mki67 score base immunohistochemistry ihc result supplementary fig s3d compare proliferation program immune expression pattern show pronounce intertumor heterogeneity malignant cell sclcp2 fig 3e accordance enrichment infiltrate immune cell reorder cell hypoxiarelated hallmark also reveal gradient sample fig 3f indicate heterogeneous malignant component might associate variable biological process angiogenesis nutritionalblood supply tumor metastasis validate ith diverse transcriptional program publish singlecell data supplementary fig s3eg together data reveal recurrent feature tumor cell heterogeneity sclc i.e. expression diverse transcriptional program great potential better understand sclc biology optimize current treatment develop new therapeutic strategy sclc although sclc consider molecularly homogeneous malignancy recent analysis lead classification molecular subtypes base intertumor heterogeneity ascl1 neurod1 pou2f3 yap1 expression subtypes term sclca sclcn sclcp sclcy sclca sclcn consider sclc neuroendocrine characteristic sclcne sclca represent 'classic subtype sclcne sclcn represent 'variant subtype although populationlevel data reveal dominant transcriptional program continue explore whether individual cell tumor could vary accord classification data reveal ascl1 neurod1 pou2f3 exclusively express malignant cell sclc tumor however yap1 mainly express normal epithelial cell rather tumor cell supplementary fig s4a determine subtypes nine sclc tumor basis merge singlecell rna expression data note tumor clearly map one four subtypes sclca n 5 sclcp n 1 supplementary fig s4b none malignant cell map sclcn sclcy subtypes probably due low frequency among sclc subtypes strikingly three patient p4 p10 p11 express high level ascl1 variable level neurod1 term sclcan subtype study supplementary fig s4b examine expression ascl1 neurod1 pou2f3 individual malignant cell across tumor five sclca tumor consist cell express uniformly high level ascl1 conform bulklevel subtypes however small number cell exhibit highly divergent gene expression pattern example low level ascl1 neurod1 represent nonneuroendocrine nonne subpopulation sclca tumor fig 4a contrast three sclcan tumor consist heterogeneous malignant cell correspond different sclc subtypes sclca sclcan sclcn sclcnonne fig 4a sclcp tumor detectable expression ascl1 neurod1 consist individual cell express heterogeneous level pou2f3 half cell detectable expression pou2f3 fig 4a surprisingly sclcnonne cell sclca sclcan sclcp tumor express neither pou2f3 yap1 might suggest new subtypes dominate tfs existence transitional state supplementary fig s4c understand spatial relationship transcriptional state perform multiplex immunofluorescence stain three tfs sample image confirm presence multiple subtypes within tumor proportion similar identify scrnaseq analysis fig 4b singlecell result confirm diversity tumor cell state sclc tumor regulatory function ascl1 neurod1 tfs shape state malignant cell sclc patient better understand transcriptional relationship among malignant cell apply unsupervised inference method monocle 2 construct potential transitional trajectory unsupervised pseudotime suggest branch trajectory sclcan sclcnonne cell position opposite branch sclca cell fig 4c supplementary fig s4d faceted pseudotime trajectory reveal sclca sclcan branch mainly compose cell sclca tumor sclcan tumor respectively fig 4e supplementary fig s4e contrast sclcnonne branch include cell mainly p2 nonne cell sclcan tumor widely accept sclc derive pulmonary ne cell lung express ascl1 include 54 normal neuroendocrine normal ne cell describe vieira braga f.a. et al expect normalne cell locate start sclca branch evolutionary trajectory sclca subtypes indicate fig 4c e supplementary fig s4e determine 'roots developmental trajectory sclc apply cytotrace delineate cellular hierarchy base number express gene per cell result indicate two possible 'roots fewer differentiation state one start sclca branch fig 4f derive normal ne cell high degree differentiation sclca cell exhibit high degree dedifferentiation sclcan cell show increase degree differentiation suggest sclcan might derive sclc cell fig 4g potential 'roots sclcnonne branch mainly compose cell p2 indicate sclcp tumor could arise distinct cell origin normal ne cell fig 4f g. pou2f3 master driver tuft cell rare chemosensory cell type pulmonary epithelium find suggest sclcp tumor might arise tuft cell validation need together result confirm rationality partition use key tfs fundamental feature molecular landscape sclc compare representation sclc subtypes bulk level scrnaseq data reveal representation multiple sclc subtypes singlecell level vary ratio sclc tumor emphasize importance apply singlecell sequence signal urgent need functional study ith respect progression treatment although nonne notchactive smallcell lung cancer cell subpopulation describe genetically engineer mouse model gemms function significance human tumor remain unclear next explore functional association intratumor subtype signature across individual cell focus three sclcan tumor largest number heterogeneous cell include p4 p10 p11 base expression ascl1 neurod1 malignant cell cluster three subtypes sclca sclcan sclcn include sclcnonne fig 5a supplementary fig s5a malignant cell sclca sclcan subtypes express gene grp uchl1 chga fig 5b display typical neuroendocrine feature sclc contrast sclca cell expression neurod1 sclcan cell result significant gene expression alteration degs mainly include associate neural development neurod1 chrna3 cntn2 fig 5b sclcnonne cell number gene myc cd44 hes1 anxa12 cxcl18 17 highly express myc demonstrate gemms drive nelow variant subset sclc neurod1 expression exhibit gradually decrease expression pattern sclcnonne sclcan sclca cell supplementary fig s5b recent study suggest mycamplified sclc may sensitive aurora kinase inhibitor alisertib chk1 inhibitor suggest combinational strategy drug target sclcne population sclc treatment cd44 multifunctional cell surface adhesion receptor describe highly express nonne sclc cell associate migration invasion process involve metastasis subtype supplementary fig s5c consistent result gemms human sclc high expression hes1 supplementary fig s5d transcriptional target notch signal pathway together low expression dlk1 supplementary fig s5e indicate activate notch signal pathway cell population target heterogeneous composition sclcne sclcnonne malignant cell develop combinational treatment strategy compose etoposide cisplatin ep conventional chemotherapy sclc combination silibinin major bioactive component plant silybum marianum study extensively efficacy cancer inhibit cd44 promoter activity addition silibinin greatly enhance cancer inhibition efficacy chemotherapy sclc vitro vivo supplementary fig 5fh next perform gsea explore biological function associate three cluster compare sclcnonne cell population sclcne include sclca sclcan cell population exhibit prominent enrichment signature hallmark e2f target g2m checkpoint fig 5c supplementary fig s6a indicate relatively strong proliferation signature cell population coexpression neurod1 ascl1 might drive malignant cell 'variant subtype sclc show enrichment signature involve hallmark angiogenesis emt supplementary fig s6b would promote tumor cell survival metastasis 'hybrid state might indicate biological plasticity subtypes shape microenvironment tumor progression contrast sclcnonne cluster relatively low proliferation ability exhibit prominent enrichment signature involve hallmark tnfa signal via nfκb interferon α response interferon γ response indicate close interaction immune component sclc microenvironment fig 5c supplementary fig s6c describe heterogeneous characteristic subtypes analyze gene expression score cell cycle immune hypoxiarelated hallmark describe previous section accordance gsea result cell sclcne subtype include sclca sclcan exhibit higher cell cycle score sclcnonne subtype exhibit highest immune hypoxiarelated hallmark score fig 5df supplementary fig s6df ith sclc infer tf expression associate short diseasefree survival dfs time surgical treatment study fig 5g addition also perform immunohistochemistry ihc formalinfixed paraffinembedded ffpe tissue large cohort 90 sclc patient supplementary table s5 expression ascl1 neurod1 evaluate protein level supplementary fig s6g result indicate heterogeneous expression ascl1 neurod1 associate relatively short overall survival o supplementary fig s6h use cellphonedb illustrate interact molecule ligandreceptor pair confirm sclcnonne cluster tend interaction cell cluster immune stromal cell supplementary fig s6i j. cd74copa cd74app c5ar1rps19 significantly enrich three sclc cluster macrophagesmonocytesdcs specific pair enrich different sclc cluster fig 5hj supplementary table s6 brief although populationlevel data reveal dominant transcriptional program singlecell transcriptional data reveal intratumor subtype heterogeneity potentially provide important insight sclc tumor biology clinical implication sclc treatment gain insight potential determinant sclc relapse closely monitor patient three year ultimately obtain one fineneedle biopsy sample relapse sclcp2 cell cluster contain cell pt rt cell nat identify myeloid cell supplementary fig s7a b. isolate malignant cell pt rt umap reveal three cluster two pt one rt fig 6a b overlap cluster compose cell origin deg analysis gsea reveal pt cell exclusively express immuneassociated gene hallmark rt cell mainly express hypoxia apoptosisassociated gene pathway fig 6c d. consistent signature pt rt mainly enrich cell cycleassociated hallmark e2ftargets g2mcheckpoint mitoticspindle represent subpopulation pt rt high proliferation activity pou2f3 expression consistent tumor relapse supplementary fig s7c consistent expression level malignant cell pt rt gain insight potential determinant sclc recurrence deduce cnvs pt rt p2 supplementary fig s7d rt exhibit cnv pattern similar pt include deletion 3p 4p 4q 10q deletion 13q contain rb1 16q loss 17p contain tp53 result indicate although significant genomiclevel alteration tumor recurrence transcriptional evolution occur tumor relapse heterogeneous expression pattern immuneassociated property malignant cell well immune component suggest sclc might different immune microenvironments associate distinct subtypes prompt u extract additional insight bulk sclc data first download bulk expression data 50 sclc cell line cancer cell line encyclopedia ccle categorize accord key tfs ascl1 neurod1 pou2f3 yap1 supplementary fig s8a immune signature cell line reveal heterogeneous intertumor immune profile half 2550 cell line express strong immune characteristic fig 7a term 'immune hot half express weak immune characteristic 'immune cold immune hot tumor refer immune cell wellinfiltrated tumor whereas immune cold tumor refer immune cell poorly noninfiltrated tumor associate immunotherapy response many cancer type data also reveal sclcs ne characteristic include sclca sclcn tend 'immune cold character nonne sclcs include sclcp sclcy tend 'immune hot characteristic fig 7b validate result download bulk expression data 81 human sclc tumor describe george et al. include data malignant cell stromal cell infiltrate immune cell relative frequency four subtypes similar ccle cell line accordance describe review rudin et al. sclca frequent subtype supplementary fig s8b data also reveal sclcne tumor exhibit cold immune characteristic 4569 65 fig 7c nonne sclc tumor tend exhibit hot immune characteristic 1012 83 fig 7d investigate whether change immune stromal cell type component tme correlate sclc tumor different immune characteristic use mcpcounter method deduce relative abundance heterogeneous cell population base bulk gene expression data result indicate sclc tumor exhibit hot immune signature associate immune stromal cell infiltration fig 7e deduce whether sclc tumor different immune property would associate different immune checkpoint blockade icb response perform target gene expression analysis 14 sample sclc patient receive antipd1 treatment base immune gene four patient identify 'immune hot feature patient n 10 identify 'immune cold feature close followup 20 month data indicate patient 'immune cold sclc tend benefit icb patient immune hot sclc find suggest significant intertumor heterogeneity ith sclc regard immune characteristic warrant validation large